PGNYProgyny, Inc. Common Stock — stock analysis & sentiment

At $31.13, the stock is trading close to the upper end of its 52-week range of $16.10 to $33.06 — within a few percent of the high, and roughly double the low. That is a wide band for twelve months: the distance between the extremes is nearly as large as the low itself, so the past year has involved substantial repricing rather than a steady drift, and the current level sits at the top of that span.

The valuation figures point in two different directions depending on which earnings you use. The trailing multiple of about 40 reflects a small profit base — a net margin near 5% on revenue that grew only about 1.4% — while the forward multiple of roughly 14 reflects expectations of considerably higher earnings ahead. The gap between those two numbers is the main thing the valuation data shows: the market is pricing the business off anticipated earnings well above what it has recently reported. A price-to-book near 5.5 places most of the roughly $2.4 billion market capitalization in expectations rather than balance-sheet assets, and a beta of about 1.0 indicates the shares have moved broadly in line with the market rather than amplifying it.

The recent news flow is company-specific rather than sector-wide. Most items are scheduling notices for quarterly results — the fourth-quarter and full-year 2025 report, the first quarter of 2026 — plus an appearance at a healthcare conference in May 2026. The remainder concerns insider activity and past results: a CFO share sale reported in June 2026, a CEO purchase of $1.9 million of stock in December 2025, an earnings beat in February 2025, and a sharp single-day move in November 2025. Nothing in the flow centers on broader healthcare-plan industry developments.